Rx To Go: Advancing Patient-Centric Cancer Care with Unparalleled Growth

Fort Myers, Fla., December 20, 2024 – Florida Cancer Specialists & Research Institute, LLC (FCS) a national leader in community oncology, is proud to highlight the remarkable achievements of its medically integrated pharmacy, Rx To Go, which has delivered personalized, compassionate support to nearly 16,000 patients this year. Combined with these efforts, Rx To Go has reached a significant milestone, surpassing $1 billion in annual revenue, reflecting 10% year-over-year growth.

FCS Chief Value and Procurement Officer Paul Chadwick, who oversees all pharmacy operations for the statewide practice, shared: “This milestone is not just about growth—it’s a reflection of the exceptional dedication of our comprehensive oncology pharmacy team to deliver timely and personalized care to every patient. Our focus has always been on streamlining access to medications, improving adherence, and ensuring every patient interaction is meaningful.”

Rx To Go is designed to simplify access to critical oral cancer medications and support patients at every step of their treatment journey. This year, the pharmacy has dispensed nearly 95,000 prescriptions, ensuring that patients are able to stay on track with their prescribed therapies. While achieving this milestone, Rx To Go has continued to prioritize patient care and outcomes while enhancing the level of service it provides, as evidenced by:

• Patient Satisfaction: Rx To Go currently holds a 96.1% year-to-date rating in patient satisfaction, demonstrating a seamless and compassionate approach to care.
• Patient Adherence: A 98% medication possession ratio (MPR) reinforces the medically integrated pharmacy’s ability to help patients maintain access to their life-saving therapies.
• Call Center Performance: Calls to Rx To Go are answered in an average of just 11 seconds, ensuring timely support and responsiveness to patients when they need it most.

“Rx To Go’s impressive performance metrics not only underscore our commitment to patient care but also highlight the strength of our operational model,” said FCS Chief Executive Officer Nathan H. Walcker.  “Achieving over $1 billion in revenue and maintaining high patient satisfaction and adherence rates demonstrates the effectiveness of our integrated approach. These results are a prime example of how we continue to position our practice as a leader in the oncology space and reaffirm our ability to deliver both exceptional care and sustainable growth.”

Rx To Go is a cornerstone of FCS’ mission to deliver world-class, patient-centered, innovative oncology care close to home. By streamlining medication access, offering expert guidance, and fostering adherence, the pharmacy continues to improve outcomes and enhance the patient experience.

FCS and Rx To Go remain committed to advancing the future of oncology care through continuous innovation and an unrelenting focus on patients’ needs.

Click here to learn more about Rx To Go.